| 特集名 | 潰瘍性大腸炎の治療の最先端 | |
|---|---|---|
| 題名 | 5-ASA(Aminosalicylic Acid）の使い方 | |
| 発刊年月 | 1997年 09月 | |
| 著者 | 棟方 昭博 | 弘前大学医学部第一内科学教室 |
| 【 要旨 】 | 5-ASA製剤はSASPの副作用のおもな原因とされるSPを含まないことから，高い安全性を特長とする製剤である．したがって，SASPで生じる不耐性や男性不妊，尿着色などの問題を抱える症例に対しても5-ASA製剤は投与可能である． 本邦におけるSASPを対照とした二重盲検比較試験では，欧米の報告と同様に安全性が高いことが確認されるとともに，慢性持続型では有意に5-ASA製剤の改善率が勝っていた． 同じ5-ASA量のSASPと5-ASA製剤を比較すると，同等の効果が得られている．しかし，5-ASA製剤は、投与量に相関する副作用がみられないことから，より高い治療効果が得られる至適用量の検討が必要である． |
|
| Theme | Advanced Therapy Ulcerative Colitis | |
|---|---|---|
| Title | The Use of Mesalazine | |
| Author | Akihiro Munakata | First Department of Internal Medicine, Hirosaki University School of Medicine |
| [ Summary ] | 5-Aminosalicylic acid (5-ASA) is the active portion of salazosulfapyridine (SASP), used in the treatment of inflammatory bowel disease. The oral mesalazine preparations has been recognized as being less toxic than SASP. The majority of adverse effects encountered with SASP, including male infertility, orange urine and so forth, are thought to be related to the sulfa moiety. A double-blind, comparative study of the efficacies of mesalazine (Pentasa) and SASP was carried out in patients with mildly to moderately active ulcerative colitis. Overall, 85.7% of patients with the chronic continuous type, being treated with mesalazine, showed improvement in sigmoidoscopic appearance and symptoms as compared with 25% on SASP. It appears that administration of 5-ASA amounts equivalent to those of SASP are sufficient in patients with active ulcerative colitis. Since dose-related adverse effects have not been observed with any of the oral mesalazine preparations, additional dose-response studies are necessary to establish optimal therapeutic doses. |
|